Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWENOTECA-ABC: Adjuvant BEP vs Carboplatin in Stage I Seminoma
NCT02341989Phase 3Active, not recruiting
- Sponsor
- St. Olavs University Hospital
- Start
- Apr 2015
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bleomycin, etoposide and cisplatin in seminoma (testicular) (2 arms), sponsored by St. Olavs University Hospital. Primary endpoint: Relapse rate at 10 years. Started Apr 2015; status: active, not recruiting.
02
Drugs
bleomycinetoposidecisplatin
03
Conditions
seminoma (testicular)
Beyond the preview
Go deeper on NCT02341989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341989.